San Diego-based Gossamer Bio, which in July snagged a $230 million series B round, recently announced the hire of a former executive from pharmaceutical giant Bristol-Myers Squibb.

Luisa Salter-Cid, previously vice president and head of immunology at Bristol-Myers Squibb, was named as Gossamer’s chief scientific officer.

“The team and pipeline of innovative and transformative medicines that Gossamer Bio has assembled are truly exciting,” Salter-Cid, said in a news release.

During 13 years at Bristol-Myers Squibb, where she climbed the ladder, Salter-Cid advanced more than 20 compounds into clinical development.

Gossamer, which emerged in January, has three potential treatments in clinical trials and one in the research stage, with more to follow, according to the company.

Salter-Cid has also held positions at La Jolla Pharmaceuticals, Genset Corp and Johnson & Johnson.